New global trial testing oral therapy for MS spasticity
UC expert featured in MS News Today article
The University of Cincinnati's Shahla Hosseini, MD, PhD, was featured in a Multiple Sclerosis (MS) News Today article discussing a new international clinical trial testing an oral drug that enhances naturally occurring molecules in the body to help muscles relax as a treatment for spasticity in patients with MS.
Many patients with MS experience spasticity, which causes muscles to resist being stretched, leading to pain, impaired function, decreased mobility and poorer quality of life.
“Physicians who treat muscle spasticity have a limited number of medications from which to choose. In the past 20 to 30 years, we haven’t seen development of new effective oral medications to treat spasticity in the United States,” said Hosseini, adjunct associate professor of Physical Medicine and Rehabilitation in the Department of Neurology and Rehabilitation Medicine in UC’s College of Medicine and a UC Health physician. “The majority of the currently available oral medications have side effects like drowsiness, which limits their usefulness during the daytime, and so we really need a new effective treatment for spasticity that’s better tolerated by patients.”
The body naturally produces molecules called endocannabinoids that help muscles relax and play a role in other functions, including regulating mood, pain and sleep, Hosseini explained. The trial drug is designed to inhibit two enzymes that break down endocannabinoids, monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), allowing the endocannabinoids to help regulate the overly reactive spastic muscles.
Read the MS News Today article.
Featured photo at top of a person with knee stiffness. Photo/PonyWang/iStock Photo.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.